BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research note issued on Thursday. The firm set a “hold” rating on the medical technology company’s stock.

BIOL has been the subject of a number of other research reports. Maxim Group started coverage on BIOLASE in a report on Friday, March 18th. They issued a “buy” rating and a $37.50 price target for the company. Colliers Securities reiterated a “buy” rating on shares of BIOLASE in a research note on Tuesday, March 22nd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $43.75.

Shares of BIOL stock opened at $5.58 on Thursday. BIOLASE has a 1-year low of $4.21 and a 1-year high of $23.49. The stock’s fifty day moving average price is $10.18 and its 200 day moving average price is $10.74. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.63. The company has a market cap of $861.25 million, a price-to-earnings ratio of -2.03 and a beta of 1.64.

BIOLASE (NASDAQ:BIOL – Get Rating) last issued its quarterly earnings results on Thursday, March 17th. The medical technology company reported ($0.75) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.75). BIOLASE had a negative return on equity of 62.78% and a negative net margin of 41.23%. The company had revenue of $12.41 million during the quarter. During the same period in the prior year, the firm posted ($1.75) EPS.

Large investors have recently bought and sold shares of the stock. Morgan Stanley purchased a new position in shares of BIOLASE during the first quarter worth about $34,000. Commonwealth Equity Services LLC purchased a new position in shares of BIOLASE during the third quarter worth about $31,000. Essex Investment Management Co. LLC purchased a new position in shares of BIOLASE during the third quarter worth about $511,000. Geode Capital Management LLC grew its holdings in shares of BIOLASE by 9.5% during the third quarter. Geode Capital Management LLC now owns 1,323,471 shares of the medical technology company’s stock worth $846,000 after buying an additional 114,432 shares during the last quarter. Finally, Credit Suisse AG purchased a new position in shares of BIOLASE during the third quarter worth about $29,000. 11.38% of the stock is currently owned by hedge funds and other institutional investors.

About BIOLASE (Get Rating)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.

Further Reading